ECSP066595A - Anticuerpo del receptor anti-igf-i - Google Patents

Anticuerpo del receptor anti-igf-i

Info

Publication number
ECSP066595A
ECSP066595A EC2006006595A ECSP066595A ECSP066595A EC SP066595 A ECSP066595 A EC SP066595A EC 2006006595 A EC2006006595 A EC 2006006595A EC SP066595 A ECSP066595 A EC SP066595A EC SP066595 A ECSP066595 A EC SP066595A
Authority
EC
Ecuador
Prior art keywords
antibodies
igf
cancer
receptor
elevated levels
Prior art date
Application number
EC2006006595A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Tavares
Rajeeva Singh
Nancy E Dagdigian
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of ECSP066595A publication Critical patent/ECSP066595A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
EC2006006595A 2003-12-08 2006-05-31 Anticuerpo del receptor anti-igf-i ECSP066595A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody

Publications (1)

Publication Number Publication Date
ECSP066595A true ECSP066595A (es) 2006-10-17

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006595A ECSP066595A (es) 2003-12-08 2006-05-31 Anticuerpo del receptor anti-igf-i

Country Status (13)

Country Link
EP (1) EP1692176A4 (pt)
JP (1) JP2008502589A (pt)
KR (1) KR20070001883A (pt)
CN (1) CN1886424A (pt)
AU (1) AU2004303792A1 (pt)
BR (1) BRPI0417406A (pt)
CA (1) CA2548065A1 (pt)
CR (1) CR8426A (pt)
EA (1) EA009807B1 (pt)
EC (1) ECSP066595A (pt)
IL (1) IL174770A0 (pt)
MX (1) MXPA06005540A (pt)
NO (1) NO20063155L (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
CA2800311A1 (en) * 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
CA3056573A1 (en) * 2017-05-30 2018-12-06 Teijin Pharma Limited Anti-igf-i receptor antibody
EP4678186A1 (en) * 2023-03-07 2026-01-14 Akeso Pharma Co., Ltd. Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143514A0 (en) * 1998-12-04 2002-04-21 Novartis Ag METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ3
NZ527302A (en) * 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
KR20050109489A (ko) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도

Also Published As

Publication number Publication date
JP2008502589A (ja) 2008-01-31
EP1692176A4 (en) 2008-11-12
AU2004303792A1 (en) 2005-07-07
EA200600931A1 (ru) 2006-10-27
EP1692176A1 (en) 2006-08-23
NO20063155L (no) 2006-08-11
IL174770A0 (en) 2006-08-20
KR20070001883A (ko) 2007-01-04
EA009807B1 (ru) 2008-04-28
MXPA06005540A (es) 2006-08-17
CR8426A (es) 2007-12-04
CA2548065A1 (en) 2005-07-07
BRPI0417406A (pt) 2007-04-03
CN1886424A (zh) 2006-12-27

Similar Documents

Publication Publication Date Title
SG141243A1 (en) Anti-igf-i receptor antibody
AR061911A1 (es) Anticuerpo antagonista para el tratamiento del cancer
ES2571235T3 (es) Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
UA94388C2 (ru) Антиинтегриновый иммуноконьюгат и способы лечения с его помощью
NO20070945L (no) Induksjon av apoptose i tumorceller som uttrykker toll-lignende reseptor
GT200600324A (es) Nuevos anticuerpos anti-igf-ir y usos de los mismos
AR061245A1 (es) Composiciones y metodos para la modulacion del desarrollo vascular
CU20130130A7 (es) Anticuerpos tipo receptor de células t específicos para un péptido wt1 presentado por hla-a2
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
DOP2013000045A (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
EA032908B1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
EA202193309A1 (ru) Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы
WO2007100640A3 (en) Growth hormone receptor antagonist cancer treatment
PH12021552379A1 (en) Anti-egfrviii antibodies and antigen-binding fragments thereof
CR8426A (es) Anticuerpo del receptor anti-igf-i
CO6331345A2 (es) Composiciones y métodos que proporcionan una línea celular de hibridoma depositada como no. de acceso atcc pta-9387 y un anticuerpo producido por esta línea celular de hibridoma
EA200601405A1 (ru) Гуманизированное антитело
MX2024011939A (es) Nuevo inhibidor de mcl-1 y combinacion de mcl-1 y un mimetico de bh3, tal como un inhibidor de bcl-2
DOP2009000003A (es) Anticuerpo antagonista para el tratamiento del cancer
Cadden An investigation into the role of oncoproteins in neuroendocrine tumour development.